RA Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

RA Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$219M	Buy	2,611,733 +1,000,000	+62%	+$57.9M	2.32%	9
2025 Q4	$66.4M	Sell	1,611,733 -1,255,000	-44%	-$48.7M	0.68%	30
2025 Q3	$113M	Hold	2,866,733	–	–	1.39%	17
2025 Q2	$53.4M	Hold	2,866,733	–	–	0.9%	26
2025 Q1	$52M	Buy	2,866,733 +1,000,333	+54%	+$22M	0.87%	23
2024 Q4	$40.7M	Sell	1,866,400 -466,600	-20%	-$12M	0.54%	38
2024 Q3	$63.9M	Hold	2,333,000	–	–	0.74%	31
2024 Q2	$60.4M	Hold	2,333,000	–	–	0.8%	33
2024 Q1	$70M	Buy	+2,333,000	New	+$50.7M	0.89%	30
2022 Q4	–	Sell	-224,255	Closed	-$5.06M	–	73
2022 Q3	$5.06M	Buy	+224,255	New	+$6.14M	0.11%	69

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's DNTH Position: Q1 2026 in Review

RA Capital Management increased its Dianthus Therapeutics (DNTH) stake by 62% in Q1 2026, buying an estimated $57.9M and bringing the position to 2,611,733 shares worth $219M. The position accounts for 2.32% of the portfolio, ranked #9.

RA Capital Management first reported a position in DNTH in Q3 2022 and has held it in 10 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

RA Capital Management held 2,611,733 shares of Dianthus Therapeutics worth $219M as of Q1 2026.
RA Capital Management bought 1,000,000 Dianthus Therapeutics shares in Q1 2026, an estimated $57.9M.
Dianthus Therapeutics made up 2.32% of RA Capital Management's portfolio in Q1 2026, its #9 holding.
RA Capital Management first reported a position in Dianthus Therapeutics in Q3 2022 and has held it in 10 quarters since.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.